CareDx (CDNA) Expected to Announce Quarterly Earnings on Tuesday

CareDx (NASDAQ:CDNA) is projected to post its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect CareDx to post earnings of $0.24 per share and revenue of $102.7560 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

CareDx Trading Up 2.8%

Shares of NASDAQ:CDNA opened at $19.63 on Tuesday. The firm has a market cap of $1.01 billion, a PE ratio of 16.50 and a beta of 2.51. The company has a fifty day simple moving average of $19.73 and a 200 day simple moving average of $16.45. CareDx has a 12-month low of $10.96 and a 12-month high of $25.55.

Insiders Place Their Bets

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total transaction of $407,964.80. Following the completion of the sale, the chief executive officer directly owned 597,405 shares in the company, valued at $12,641,089.80. The trade was a 3.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders sold 29,636 shares of company stock valued at $625,949. Corporate insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Deerfield Management Company L.P. bought a new position in CareDx in the 3rd quarter worth $31,857,000. Boston Partners grew its holdings in shares of CareDx by 2,776.5% in the 4th quarter. Boston Partners now owns 901,929 shares of the company’s stock valued at $16,994,000 after buying an additional 870,574 shares during the period. Millennium Management LLC increased its position in shares of CareDx by 504.0% in the 3rd quarter. Millennium Management LLC now owns 413,689 shares of the company’s stock valued at $6,015,000 after buying an additional 345,197 shares in the last quarter. Palo Alto Investors LP acquired a new stake in CareDx during the 3rd quarter worth $4,598,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of CareDx by 26.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,216,524 shares of the company’s stock valued at $17,690,000 after purchasing an additional 253,739 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have issued reports on CDNA shares. Weiss Ratings restated a “hold (c-)” rating on shares of CareDx in a research note on Monday, December 29th. Zacks Research raised CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Wells Fargo & Company increased their price target on CareDx from $14.00 to $18.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Craig Hallum lowered shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective for the company. in a research report on Tuesday, January 6th. Finally, Wall Street Zen lowered CareDx from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $26.67.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.